By signing up you consent to receive the above newsletter from Postmedia Network Inc.Thanks for signing up!A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox. ...

Core Insights - Canopy Growth Corporation (NASDAQ:CGC) reported Q1 FY2026 net revenue of $72.1 million, representing a 9% year-over-year increase driven by a 13% rise in medical cannabis sales and a 43% increase in adult-use cannabis sales in Canada [1] - The company experienced a decline in consolidated gross margin from 35% to 25% due to lower high-margin sales in Poland and a shift towards higher-cost manufactured products [1] - The net loss from continuing operations decreased by 21% to $23 million, while SG&A expenses also fell by 21% as part of $17 million in annualized cost savings [1] Financial Performance - Q1 FY2026 net revenue: $72.1 million, up 9% year-over-year [1] - Medical cannabis sales increased by 13% [1] - Adult-use cannabis sales in Canada rose by 43% to $27 million [1] - International cannabis revenue increased by 5% to $8.8 million [1] - Storz & Bickel vaporizer revenue decreased by 25% to $15.1 million [1] - Consolidated gross margin declined from 35% to 25% [1] - Net loss from continuing operations fell by 21% to $23 million [1] - SG&A expenses decreased by 21% [1] - Cash and short-term investments rose to $144 million [1] Strategic Outlook - CEO Luc Mongeau highlighted significant share growth in cannabis markets with high demand [2] - Interim CFO Tom Stewart noted improving gross margins as a key target for FY2026 [2] - A new Storz & Bickel vaporizer is set to be introduced later in 2025 [2] - The company anticipates that automation and increased PRJ production will enhance margins in the second half of FY2026 [2]

Industry Overview - The Canadian cannabis sector is crucial for investors looking to tap into the expanding U.S. marijuana market, which generated over $33 billion in sales in 2024 and is projected to exceed $50 billion by 2030 due to increasing state-level legalization and consumer demand [1][3] - Recent discussions around federal reform and rescheduling cannabis could benefit Canadian companies with U.S. partnerships or expansion plans, making them attractive to investors [1][3] Company Highlights - **Tilray Brands, Inc. (TLRY)**: - Operates in cultivation, processing, and distribution across Canada, Europe, and the U.S., focusing on hemp-derived beverages and wellness products, reaching about 1,000 retail stores [5][7] - Reported annual revenue of approximately $821 million with a gross profit of around $240 million, but net income remains negative with losses exceeding $2 billion [7] - **Canopy Growth Corporation (CGC)**: - One of the largest cannabis companies in Canada, with a strong presence in the U.S. through brands and subsidiaries rather than direct dispensary ownership [8][10] - Achieved year-over-year revenue growth of about 9%, but gross margin fell to 25% from 35% a year earlier, indicating financial strain [10] - **Village Farms International, Inc. (VFF)**: - Transitioned from agricultural production to cannabis, operating one of the largest cannabis greenhouse facilities in Canada with over 2.2 million square feet [12][14] - Reported annual revenue of about $336 million, a 17% increase from the previous year, but posted a net loss of approximately $36 million [14] Strategic Focus - Tilray is diversifying through beverages and wellness products, while Canopy is focusing on cost-cutting and U.S. brand partnerships [15] - Village Farms emphasizes efficiency and international expansion, positioning itself as one of the lowest-cost producers in Canada [14][15] Market Outlook - The Canadian cannabis sector faces challenges from oversupply and regulatory uncertainty, but leading companies are adapting their strategies to remain competitive [15][16] - September 2025 is seen as a critical period for the sector, with investors closely monitoring earnings, cost controls, and expansion efforts [16]

Core Viewpoint - Canopy Growth Corporation has launched a new at-the-market equity program to raise up to $200 million in common shares, aimed at supporting strategic investments and working capital [1][2]. Group 1: Equity Program Details - The new equity program allows for the issuance and sale of up to $200 million in common shares across U.S. and Canadian markets, with Canadian sales capped at $50 million [2]. - The program is governed by an equity distribution agreement dated August 29, 2025, with BMO Nesbitt Burns Inc. and BMO Capital Markets Corp. as agents [3]. - The program will remain active until June 5, 2027, or until the full $200 million is raised, with the Canadian portion ending earlier on July 5, 2026, or upon reaching its $50 million cap [3]. Group 2: Company Overview - Canopy Growth Corporation operates in the cannabis industry, producing and selling cannabis, hemp, and related products across Canada, Germany, and Australia [4]. - The company operates through four segments, including Canada Cannabis and International Markets, offering a variety of products such as dried flower, pre-rolls, edibles, vapes, oils, and concentrates [4]. - Canopy Growth markets its products under multiple brands, including Tweed, 7ACRES, Spectrum Therapeutics, Storz & Bickel, Wana, and DOJA [4].

the "Company†), a world-leading manufacturer of high-end, medically certified cannabis vaporizers and a subsidiary of Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC), today unveiled the VEAZY— an accessible new addition to its premium portfolio, extending the Company's precision engineering to a broader audience. The VEAZY delivers an uncompromising solution, designed to be as approachable as it is easy t. TUTTLINGEN, Germany--(BUSINESS WIRE)--STORZ & BICKEL GmbH ("STORZ & BICKEL†or ...

Industry Overview - The Canadian cannabis sector is gaining investor attention as the U.S. market approaches broader reform, with the U.S. cannabis market projected to reach approximately $38.5 billion in 2024 and grow at a CAGR of 11-12% through the late 2020s [1][3] - Legislative changes in the U.S., such as Delaware's adult-use cannabis sales starting August 1, 2025, and potential federal rescheduling of marijuana, are creating strong thematic tailwinds for Canadian cannabis stocks with U.S. exposure [1][3] Company Highlights Tilray Brands (TLRY) - Tilray has established a strong global identity by combining cannabis, wellness, and beverages, significantly expanding its U.S. footprint through acquisitions [4][6] - The company reported record revenue exceeding $820 million for fiscal 2025, with gross margins averaging around 40%, showcasing strong cost management [8][9] - Tilray's strategic pivot into hemp-based beverages and wellness products allows it to build a presence in the U.S. market despite federal restrictions [10][7] Canopy Growth Corporation (CGC) - Canopy Growth is recognized as a leading cannabis company in Canada, with ambitions to enter the U.S. market through strategic partnerships and acquisitions, notably its option to acquire Acreage Holdings [10][12] - The company generated nearly $300 million in revenue but reported a net loss exceeding $650 million, highlighting ongoing profitability challenges [14][15] - Canopy's U.S. strategy is designed to unlock value upon legalization, with a strong brand portfolio and rights to Acreage Holdings representing potential growth [16] Village Farms International (VFF) - Village Farms operates in both agriculture and cannabis, leveraging its expertise in greenhouse cultivation to strengthen its cannabis operations in Canada [18][19] - The company reported net income above $25 million in 2025, with adjusted EBITDA reaching nearly 30% of total sales, demonstrating strong profitability and revenue growth [20] - Village Farms' focus on cultivation efficiency and vertical integration has allowed it to achieve profitability, distinguishing it from many cannabis peers [20][21] Conclusion - Tilray, Canopy Growth, and Village Farms each demonstrate unique strategies for growth and financial improvement in the evolving cannabis landscape [21] - These companies are well-positioned to capitalize on potential U.S. legalization and changing market dynamics, offering various investment opportunities [21]

Industry Overview - The cannabis sector has faced a prolonged slump due to the lack of federal reforms, but recent comments from President Trump regarding marijuana rescheduling have sparked renewed optimism, leading to a surge in share prices [1] - A potential federal reclassification could significantly transform the industry by easing tax burdens, improving access to banking services, and facilitating broader medical and recreational adoption, with the market expected to exceed $160 billion by 2032 [2] Company Analysis: Village Farms International (VFF) - Village Farms International holds a Zacks Rank 1 and is one of the few cannabis operators consistently generating positive EBITDA and cash flow, with Q2 earnings showing a 690% year-over-year increase in international medical export sales [4][6] - The company has divested its lower-margin fresh-produce business to focus on higher-margin cannabis operations, maintaining its position as one of Canada's top three cannabis players and contributing $2.4 million in incremental Q2 revenues from shipments to the Netherlands [5] - EPS estimates for VFF have improved significantly, with 2025 estimates rising from a loss of 9 cents to earnings of 12 cents, and the stock has increased nearly 274% year to date [6] Company Analysis: Canopy Growth (CGC) - Canopy Growth, with a Zacks Rank 2, has been streamlining operations by exiting lower-margin businesses and selling non-core assets to enhance liquidity and reduce operating expenses [7] - The company's U.S. strategy through Canopy USA provides exposure to key recreational and medical cannabis markets, and federal rescheduling could accelerate the commercialization of its U.S. assets, creating new revenue streams [8] - Loss per share estimates for CGC have narrowed from 57 cents to 50 cents for 2025, and despite a 55% decline in stock price year to date, improvements in top- and bottom-line metrics are encouraging for investors [9] Company Analysis: High Tide (HITI) - High Tide, also holding a Zacks Rank 2, is recognized as one of Canada's fastest-growing cannabis retailers, operating over 170 branded retail locations and leveraging both physical and online sales channels [10] - Loss per share estimates for HITI have improved from 5 cents to 4 cents for 2025, with 2026 EPS rising from 5 cents to 11 cents, and the stock has seen a 9% increase, driven by strong operational performance and optimism regarding federal marijuana rescheduling [11][12]

Group 1 - The U.S. industrial hemp sector showed strong performance on Monday, with notable gains in several companies [1] - Tilray (TLRY.US) increased by over 8.9%, OrganiGram Holdings (OGI.US) rose by more than 6%, and Sundial Growers (SNDL.US) climbed nearly 4% [1] - Aurora Cannabis (ACB.US) saw an increase of over 2.6%, while Canopy Growth (CGC.US) surged by more than 6.5% [1]

Core Insights - Canadian cannabis firms with U.S. exposure are gaining attention due to their ability to bridge both markets, which positions them advantageously as U.S. policy shifts may provide new momentum for growth [1][2][24] - The U.S. legal cannabis market is projected to grow from approximately $37 billion in 2024 to over $91 billion by 2033, indicating a strong annual growth rate of more than 10 percent [2][24] - Recent headlines regarding potential federal reclassification of marijuana have fueled optimism, leading to a rally in cannabis stocks as traders seek follow-through momentum [3][24] Company Summaries Tilray - Tilray is one of the largest cannabis companies globally, focusing on cannabis-adjacent consumer goods in the U.S., with its beverage division being a key growth driver [5][6] - The company reported annual revenue exceeding $820 million, but also a significant net loss of over $2 billion, highlighting the need for tighter cost control despite strong performance in certain divisions [9][11] - The beverage segment achieved gross margins of around 40 percent, indicating strong consumer demand and pricing power [10] Village Farms International - Village Farms operates large-scale greenhouses, supplying cannabis in both Canada and the U.S., with a focus on efficient production rather than retail [12][14] - The company emphasizes wholesale supply to licensed retailers, which reduces capital costs and lowers risk while controlling significant production volumes [12][14] - Recent financial results show steady progress, with Canadian cannabis sales increasing year over year, benefiting from rising demand and improving margins [15][16] Canopy Growth - Canopy Growth is known for its broad product portfolio, including flower, pre-rolls, edibles, and wellness products, and has a presence in the U.S. through licensing and partnerships [17][20] - The company reported strong growth in Canadian medical cannabis sales, reaching $77 million, while international sales showed slight declines [21][22] - Canopy's gross margins expanded by 300 basis points year over year, and it reduced total debt by nearly 50 percent, indicating progress in strengthening its balance sheet [21][22] Market Outlook - The U.S. cannabis market's expansion presents significant opportunities for Canadian firms with U.S. exposure, particularly as potential rescheduling of marijuana could reduce restrictions and enhance valuations [2][24] - Volatility in the sector remains high, making technical analysis and risk management essential for investors looking to participate in the growth story [4][25]

Core Viewpoint - Canopy Growth (NASDAQ: CGC) experienced a 24% increase in stock price following President Trump's announcement regarding the potential rescheduling of cannabis in the upcoming weeks, indicating a significant opportunity for expansion into the U.S. cannabis market [1]. Group 1: Company Insights - Canopy Growth is strategically positioned to expand into U.S. cannabis markets through its subsidiary, Canopy USA [1]. Group 2: Industry Context - The announcement from the Trump administration suggests a potential shift in cannabis regulation, which could benefit Canadian licensed producers (LPs) like Canopy Growth [1].